- Home
- BYSI vs IKNA Comparison
BYSI vs IKNA Comparison
Compare BYSI & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- IKNA
- Stock Information
- Founded
- BYSI 2010
- IKNA 2016
- Country
- BYSI United States
- IKNA United States
- Employees
- BYSI N/A
- IKNA N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- IKNA Health Care
- Exchange
- BYSI Nasdaq
- IKNA Nasdaq
- Market Cap
- BYSI 71.0M
- IKNA 61.8M
- IPO Year
- BYSI 2017
- IKNA 2021
- Fundamental
- Price
- BYSI $3.15
- IKNA $1.36
- Analyst Decision
- BYSI
- IKNA Strong Buy
- Analyst Count
- BYSI 0
- IKNA 1
- Target Price
- BYSI N/A
- IKNA $4.00
- AVG Volume (30 Days)
- BYSI 140.7K
- IKNA 95.6K
- Earning Date
- BYSI 08-11-2025
- IKNA 08-07-2025
- Dividend Yield
- BYSI N/A
- IKNA N/A
- EPS Growth
- BYSI N/A
- IKNA N/A
- EPS
- BYSI N/A
- IKNA N/A
- Revenue
- BYSI N/A
- IKNA N/A
- Revenue This Year
- BYSI N/A
- IKNA N/A
- Revenue Next Year
- BYSI N/A
- IKNA N/A
- P/E Ratio
- BYSI N/A
- IKNA N/A
- Revenue Growth
- BYSI N/A
- IKNA N/A
- 52 Week Low
- BYSI $0.98
- IKNA $0.97
- 52 Week High
- BYSI $3.44
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- BYSI 72.10
- IKNA 56.43
- Support Level
- BYSI $2.73
- IKNA $1.10
- Resistance Level
- BYSI $3.44
- IKNA $1.46
- Average True Range (ATR)
- BYSI 0.33
- IKNA 0.07
- MACD
- BYSI 0.12
- IKNA -0.00
- Stochastic Oscillator
- BYSI 81.49
- IKNA 57.58
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.